IMA Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

IMA Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$131	Hold	1	–	–	﹤0.01%	992
2025 Q4	$141	Hold	1	–	–	﹤0.01%	979
2025 Q3	$140	Hold	1	–	–	﹤0.01%	535
2025 Q2	$126	Buy	+1	New	+$115	﹤0.01%	543

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IMA Advisory Services's NBIX Position: Q1 2026 in Review

IMA Advisory Services held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 1 share worth $131. The position accounts for ﹤0.01% of the portfolio, ranked #992.

IMA Advisory Services first reported a position in NBIX in Q2 2025 and has held it in 4 quarters since. The position peaked at $141 in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

IMA Advisory Services held 1 share of Neurocrine Biosciences worth $131 as of Q1 2026.
IMA Advisory Services left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up ﹤0.01% of IMA Advisory Services's portfolio in Q1 2026, its #992 holding.
IMA Advisory Services first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 4 quarters since.
IMA Advisory Services's Neurocrine Biosciences position peaked at $141 in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on IMA Advisory Services's 13F filing for Q1 2026, filed 6 May 2026.